← Eichor
Study identifier: NCT07689396 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Predictors of Treatment Expectations in Myofascial Pain Syndrome

Condition: Myofascial Pain Syndromes  ·  Sponsor: KTO Karatay University

PhaseN/A
Planned participants85
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This cross-sectional study aims to determine the predictors of treatment expectations in individuals with myofascial pain syndrome (MPS). MPS is one of the most common causes of musculoskeletal pain and is associated with reduced quality of life. Patients' pre-treatment expectations are known to influence clinical outcomes, yet the factors that predict these expectations have not been established. Adults diagnosed with MPS who are scheduled to receive physiotherapy complete measures of treatment expectations, pain intensity and duration, health-related quality of life, and fatigue. Multiple regression analysis is used to examine the extent to which pain intensity, pain duration, quality of life, and fatigue predict treatment expectations.

This description comes directly from the study's public registry record.

Talk to the study team

Hasan Gercek, PT, PhD  ·  +90 542 648 84 55  ·  hasan.gercek@karatay.edu.tr

Always discuss trial participation with your own doctor first.

Locations (1)

KTO Karatay UniversityKonya, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07689396